Xbrane Biopharma AB (publ) (XBRANE.ST) fair value

ACCE thesis

Xbrane Biopharma develops biosimilar versions of established biologic drugs, with its lead programmes aimed at ophthalmology and oncology, and it earns its revenue largely from development services and milestone-based partnerships rather than from selling finished products. The structural case rests on the biosimilar market, where regulators have made it easier to bring copies of expensive biologics to market and where Xbrane's own pipeline, not a commodity product line, is what it has to sell. Revenue grew 17.1% in the latest reported period, but the gross margin of 13.9% and operating margin of -6.0% show the business is still far from covering its costs, and the forward P/E of 632.5 reflects earnings that barely exist yet. The near-term question for the portfolio manager is whether the next partner milestone or regulatory filing converts the pipeline into recognised revenue. At a 261M SEK market cap with no index membership, the name is small and thinly followed, so it merits a deeper look only if the pipeline timing and cash runway can be verified against company filings.